AUDIOLOGICAL FINDINGS IN A PHASE-I PROTOCOL INVESTIGATING THE EFFECT OF WR-2721, HIGH-DOSE CISPLATIN AND RADIATION-THERAPY IN PATIENTS WITH LOCALLY ADVANCED CERVICAL-CARCINOMA

被引：23

作者：

RUBIN, JS

WADLER, S

BEITLER, JJ

HAYNES, H

ROZENBLIT, A

MCGILL, F

GOLDBERG, G

RUNOWICZ, C

机构：

[1] MONTEFIORE MED CTR,DEPT ONCOL,BRONX,NY 10467

[2] MONTEFIORE MED CTR,DEPT RADIAT ONCOL,BRONX,NY

[3] MONTEFIORE MED CTR,DEPT RADIOL,BRONX,NY

[4] ALBERT EINSTEIN COLL MED,DEPT OBSTET & GYNECOL,BRONX,NY

来源：

JOURNAL OF LARYNGOLOGY AND OTOLOGY | 1995年 / 109卷 / 08期

关键词：

CISPLATIN; OTOTOXICITY; HEARING LOSS; SENSORINEURAL; AUDIOMETRY;

D O I：

10.1017/S0022215100131202

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

WR 2721 (ethiofos) protects against the toxic effects of the heavy metal compound cisplatin, which is used in the treatment of solid tumours. In a Phase I protocol designed to determine the maximum dose of WR 2721 which could be tolerated when administered in combination with cisplatin and radiation therapy to patients with cervical carcinoma, 11 patients were evaluated by audiologic testing before and after cisplatin WR 2721 administration in an attempt to identify the degree of ototoxicity. Forty-five per cent were noted to have significant hearing threshold changes, predominantly in the high frequencies, There were no significant changes in the speech frequencies in this series. This contrasts with the greater degrees of ototoxicity observed in controls treated in the same way who received cisplatin without WR 2721 protection.

引用

页码：744 / 747

页数：4

共 39 条

[31] 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck
Bourhis, J.
Sun, X.
Le Tourneau, C.
Pointreau, Y.
Sire, C.
Kaminsky-Forrett, M-C.
Coutte, A.
Alfonsi, M.
Boisselier, P.
Martin, L.
Delord, J-P.
Clatot, F.
Biau, J.
Rolland, F.
Gollmer, K.
Szyldergemajn, S. A.
Even, C.
Tao, Y.
ANNALS OF ONCOLOGY, 2020, 31 : S1168 - S1168
[32] Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx
Hoffmann, Caroline
Calugaru, Valentin
Borcoman, Edith
Moreno, Victor
Calvo, Emiliano
Liem, Xavier
Salas, Sebastien
Doger, Bernard
Jouffroy, Thomas
Mirabel, Xavier
Rodriguez, Jose
Chilles, Anne
Bernois, Katell
Dimitriu, Mikaela
Fakhry, Nicolas
Kam, Stephanie Wong Hee
Le Tourneau, Christophe
EUROPEAN JOURNAL OF CANCER, 2021, 146 : 135 - 144
[33] Chemoradiation with ENI versus IFI, High-Dose Versus Standard-Dose Radiation Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: Preliminary Results of Multicenter, Phase III Clinical Trial (NROG 001-Northern Radiation Oncology Group of China)
Li, B.
Zhang, J.
Zhang, K.
Li, G.
Zheng, A.
Li, J.
Li, X.
Sun, X.
Chen, S.
Chen, X.
Liu, L.
Ye, S.
Liu, X.
Sheng, Y.
Ge, H.
Yu, Z.
Stchin, G.
Dai, M.
Wang, J.
Liu, S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E188 - E189
[34] Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study
Bourhis, J.
Sun, X.
Pointreau, Y.
Sire, C.
Le Tourneau, C.
Coutte, A.
Kaminsky-Forrett, M-C.
Alfonsi, M.
Boisselier, P.
Martin, L.
Delord, J-P.
Clatot, F.
Miroir, J.
Rolland, F.
Crompton, P.
Brienza, S.
Szyldergemajn, S. A.
Even, C.
Tao, Y.
ANNALS OF ONCOLOGY, 2019, 30 : 902 - 902
[35] Pemetrexed (PEM) and Cisplatin (CIS) in Concurrent Combination with High Dose of Thoracic Radiation (RT), after Induction Chemotherapy (CT), in Patients (pts) with Locally Advanced Non-small Cell Lung Cancer (NSCLC): A Phase I Study
Mornex, F.
Coudert, B.
Wautot, V.
Chouaki, N.
Bourayou, N.
Tourani, J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S501 - S502
[36] PEMETREXED (PEM) AND CISPLATIN (CIS) IN CONCURRENT COMBINATION WITH HIGH DOSE OF THORACIC RADIATION (RT), AFTER INDUCTION CHEMOTHERAPY (CT), IN PATIENTS (PTS) WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE I STUDY
Mornex, F.
Tourani, J. M.
Wautot, V.
Chouaki, N.
Vaury, A. Thareau
Bourayou, N.
Coudert, B.
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S73 - S73
[37] Phase I study of induction chemotherapy followed by intensity-modulated radiation therapy (IMRT), accelerated fractionation (AF), simultaneous integrated boost (SIB), and concomitant high dose cisplatin for locally-advanced head and neck cancer (LAHNC)
Feldman, L. E.
Agulnik, M.
Salama, J.
Ortiz, R.
Yao, M.
Pytynia, K.
Epstein, J. B.
Reisberg, D.
Minn, A.
Mundt, A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[38] DART-bid (dose-Differentiated Accelerated Radiation Therapy-1.8 Gy twice daily) with VMAT in locally advanced NSCLC: a prospective Phase I / II study. More than a Hint to promote high-dose Radiotherapy in sequential, systemic Combination?
Wurstbauer, K.
Meinschad, M.
Kazil, M.
De Vries, C.
Clemens, P.
Hernler, T.
Cerkl, P.
Kuenzler, T.
De Vries, A.
STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S86 - S87
[39] A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6).
Waldron, John N.
Parulekar, Wendy
O'Sullivan, Brian
Chen, Bingshu E.
Montenegro, Alexander
Nabid, Abdenour
Winquist, Eric
Wright, Jim R.
Hay, John
Ringash, Jolie
Martino, Rosemary
Johnson, Ana
Liu, Geoffrey
Breen, Stephen
Gilbert, Ralph William
Shenouda, George
Siu, Lillian L.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 →